The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba And Valeant

For Immediate Release

Chicago, IL – August 14, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeMylan (NASDAQ: (NASDAQ:MYL) – Free Report), Perrigo (NYSE: (NYSE:PRGO) – Free Report), Esperion Up on Positive Mid-Stage Data: Esperion’s (NASDAQ: (NASDAQ:ESPR) – Free Report),
Zynerba Plunges as STAR 1 Fails to Shine: Zynerba (NASDAQ: (NASDAQ:ZYNE) – Free Report) and Valeant Gets CRL for Eye Drop: Valeant (NYSE: (NYSE:VRX) – Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Pharma Stock Roundup: Mylan Misses, Perrigo Tops, Zynerba Plunges

Second quarter earnings season is drawing to a close with most major companies having reported results. This week, companies like Endo, Mylan (NASDAQ:MYL – Free Report), Novo Nordisk (CO:NOVOb) and Perrigo (NYSE:PRGO – Free Report) presented their second quarter results.

Recap of the Week’s Most Important Stories

A Look at Q2 Earnings Results: Mylan’s second quarter results were disappointing with the company missing on both earnings and revenues and cutting its outlook (Also read: Mylan Misses on Q2 Earnings & Sales, Lowers View). Mylan has pushed back all major product launches in the U.S. from 2017 to 2018 reflecting ongoing challenges and the uncertain U.S. regulatory environment. These product launches include generic versions of Advair and Copaxone. Escalating price erosion in the generics market remains a major challenge. Meanwhile, Mylan got a subpoena from the U.S. Department of Justice (“DOJ”) in late Jul 2017 seeking information relating to opioids manufactured, marketed or sold by the company from Jan 1, 2013 to Dec 31, 2016. Mylan has lost 15.4% of its value year to date versus the 15.8% decline of its industry.

Perrigo’s second quarter results were better-than-expected with the company raising its outlook (Also read: Perrigo Q2 Earnings & Sales Top, 2017 View Raised). Novo Nordisk also topped earnings estimates and raised its outlook. Meanwhile, Endo, which topped earnings and revenue estimates, lowered its outlook (Also read: Endo Beats Q2 Earnings & Sales, 2017 Guidance Lowered). Endo stock has lost 54.2% of its value year to date versus the 1.8% decline of its industry.

Perrigo is a Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Esperion Up on Positive Mid-Stage Data: Esperion’s (NASDAQ:ESPR – Free Report) shares were up 15.4% on positive top-line data from a study evaluating the company’s bempedoic acid and Zetia (ezetimibe) combination plus Lipitor versus placebo in patients with hypercholesterolemia. The mid-stage triplet oral therapy study met its primary endpoint of greater LDL-C lowering compared to placebo. The company intends to conduct additional studies next year and expects to file for FDA approval of the combination by the first quarter of 2019.

Zynerba Plunges as STAR 1 Fails to Shine: Zynerba (NASDAQ:ZYNE – Free Report) saw its shares plunging 55.7% on disappointing mid-stage data on the company’s experimental cannabinoid treatment, ZYN002. Results from the double-blind placebo controlled STAR 1 study in adult epilepsy patients with focal seizures showed that both doses of ZYN002 failed to meet the endpoints compared to placebo. Focus has now shifted to a couple more studies being conducted with ZYN002 – osteoarthritis (top-line data expected in Aug 2017) and Fragile X syndrome (top-line data expected in Sep 2017).

Valeant Gets CRL for Eye Drop: Valeant (NYSE:VRX – Free Report), which reported second quarter results this week (Also read: Valeant Beats Q2 Earnings, Sales in Line, Trims View), got a complete response letter (“CRL”) from the FDA for its new drug application (“NDA”) for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%). The company is looking to gain approval for the use of the intraocular pressure lowering single-agent eye drop in patients with open angle glaucoma or ocular hypertension. While no safety or efficacy concerns were raised by the FDA, the CRL referred to a Current Good Manufacturing Practice (“CGMP”) inspection at Bausch + Lomb's manufacturing facility in Tampa, FL. Valeant is working on resolving manufacturing quality issues at the Tampa plant and will be working with the agency to determine the path forward.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Get the full Report on PRGO - FREE

Get the full Report on MYL - FREE

Get the full Report on ESPR - FREE

Get the full Report on ZYNE - FREE

Get the full Report on VRX – FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.